Impact of new treatment strategies on survival in advanced ovarian cancer
Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer
This study looks at how new treatment strategies can improve survival for adults with advanced ovarian cancer who have had surgery and chemotherapy.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 130 (estimated) |
| Ages | 18 Years and up |
| Sex | Female |
| Sponsor | University Hospital, Strasbourg, France Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Strasbourg) |
| Trial ID | NCT06907771 on ClinicalTrials.gov |
What this trial studies
This observational study examines the effects of evolving therapeutic strategies on the survival of patients with advanced ovarian cancer, particularly focusing on those who have undergone radical surgeries and maintenance treatments following neoadjuvant chemotherapy. It targets adult patients diagnosed with high-grade serous carcinoma of ovarian origin at advanced stages (FIGO IIIC or IV) who were treated at the University Hospital in Strasbourg between 2010 and 2022. The study aims to gather data on patient outcomes to assess the effectiveness of these new management approaches.
Who should consider this trial
Good fit: Ideal candidates are adults aged 18 and older who have undergone specific surgical treatments for advanced ovarian cancer at the University Hospital in Strasbourg.
Not a fit: Patients with other histological types of ovarian cancer or those at earlier stages of the disease may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved survival rates for patients with advanced ovarian cancer.
How similar studies have performed: While this study builds on evolving treatment strategies, similar approaches have shown promise in improving outcomes for ovarian cancer patients.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patient (≥18 years old) * Operated on at the HUS between January 1, 2010 and December 31, 2022 * Having undergone primary or interval cytoreductive surgery * Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin Exclusion Criteria: * Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques. * Autres types histologiques de cancer de l'ovaire * Stades de la maladie FIGO I, II, IIIA et IIIC * Chirurgie de clôture.
Where this trial is running
Strasbourg
- Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France — Strasbourg, France (Recruiting)
Study contacts
- Study coordinator: Lise LECOINTRE, MD
- Email: lise.lecointre@chu-strasbourg.fr
- Phone: 33 3 88 12 75 10
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.